On Wednesday, Shares of Ericsson (ADR) (NASDAQ:ERIC), lost -0.49% to $10.15.
- Ericsson continues to spearhead 5G system development as coordinator of EU`s new METIS-II project
- The project will develop the overall 5G radio system design and roadmap recommendation for 5G, playing a key coordinating role within the 5G-PPP projects, and bringing key players together to advance 5G system architecture
- Ericsson will also take the lead as technical coordinator of the mmMAGIC project to develop a new radio interface
Ericsson (ERIC) continues to spearhead 5G system development as coordinator of the new METIS-II EU project to develop the overall 5G radio system design and roadmap recommendation for 5G standardization.
Ericsson provides communications technology and services worldwide. The companys Networks segment delivers products and solutions for mobile access, Internet protocol (IP) and transmission networks, core networks, and cloud.
Shares of Ecolab Inc. (NYSE:ECL), declined -1.39% to $110.62, during its last trading session.
Ecolab will host a live webcast of its earnings conference call to talk about second quarter results and future earnings guidance. A news release containing second quarter results and future earnings guidance is predictable to be issued before market open on July 28, 2015.
Prepared remarks and supplemental data regarding Ecolab’s results and future earnings guidance are predictable to be accessible on www.ecolab.com/investor about one hour preceding to the conference call.
Ecolab Inc. provides water, hygiene, and energy technologies and services for customers worldwide. The company operates in four segments: Global Industrial, Global Institutional, Global Energy, and Other.
Finally, Arrowhead Research Corp (NASDAQ:ARWR), ended its last trade with -2.95% loss, and closed at $6.57.
Arrowhead Research Corp, declared that it received regulatory permission in the United Kingdom and New Zealand to proceed with Part B of its Phase 1 study of ARC-AAT, Arrowhead’s RNAi-based drug candidate for the treatment of liver disease associated with the rare genetic disorder alpha-1 antitrypsin deficiency (AATD). The Phase 1 study is presently enrolling patients at a single center in Australia and, pending approval from ethics committees, the company intends to start recruiting patients at additional sites in the United Kingdom and New Zealand. Arrowhead anticipates to complete enrollment by the end of 2015.
The ongoing Phase 1 trial of ARC-AAT is a multi-center, randomized, placebo-controlled, double-blind, single dose-escalation, first-in-human study to evaluate the safety, tolerability and pharmacokinetics of ARC-AAT and the effect on circulating AAT levels. The study has been enrolling in dose cohorts of six participants each, with participants randomized at a ratio of 2:1 (active:placebo) to receive a single intravenous injection of either ARC-AAT or placebo (normal saline). The study comprises of two parts; Part A in healthy volunteers, which has been accomplished, and Part B to be conducted in patients with PiZZ genotype AATD. Dosing in patients starts at the highest dose level used in healthy volunteers and then continued dose escalation may proceed under the protocol. The study evaluates participants for 28 days following dosing, with additional follow-up if needed every 2 weeks until AAT levels return to baseline.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
